Company: MIRA
Filing Date: 2025-06-17
Form Type: PREM14A
Source: 0001641172-25-015340
Chunk: 2

Company: MIRA PHARMACEUTICALS, INC.
Filing Date: 2025-06-17
Form: PREM14A
Chunk 2
---
 the shares of MIRA Common Stock outstanding immediately prior to the Merger, pursuant to Nasdaq Listing Rule      
 5635(a) (the “Merger Proposal” or “Proposal No. 1”); and                                                                                 |
| 2. | approve                                                                                                                                  
 a postponement or adjournment of the Merger virtual special meeting, if necessary, to solicit additional proxies if there are not        
 sufficient votes in favor of Proposal No. 1 (the “Adjournment Proposal” or “Proposal No. 2”).                                            |

Please refer to the attached proxy statement for further information with respect to the business to be transacted at the MIRA virtual special meeting.

After careful consideration, MIRA’s board of directors has unanimously (i) determined that the Merger and the other transactions and actions contemplated by the Merger Agreement (the “Contemplated Transactions”) are fair to, advisable and in the best interests of MIRA and its stockholders; (ii) approved and declared advisable the Merger Agreement and the Contemplated Transactions, including the issuance of shares of MIRA common stock to the stockholders of SKNY; and (iii) determined to recommend, upon the terms and subject to the conditions set forth in the Merger Agreement, that the stockholders of MIRA vote “ FOR” Proposal Nos. 1 and 2. More information about MIRA, SKNY and the proposed transaction is contained in the accompanying proxy statement. MIRA urges you to read the accompanying proxy statement carefully and in its entirety. IN PARTICULAR, YOU SHOULD CAREFULLY CONSIDER THE MATTERS DISCUSSED UNDER “ RISK FACTORS” BEGINNING ON PAGE 12.

MIRA is excited about the opportunities the Merger brings to its stockholders, and thanks you for your consideration and continued support.

Sincerely,

Erez Aminov

Chief Executive Officer

MIRA Pharmaceuticals, Inc.

Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved the Merger described in this proxy statement or the MIRA Common Stock to be issued in connection with the Merger or passed upon the adequacy or accuracy of this proxy statement. Any representation to the contrary is a criminal offense.

The accompanying proxy statement is dated , and, together with the enclosed form of proxy card, is first being mailed to MIRA stockholders on or about , 2025.

<div align='center'>MIRA PHARMACUTICALS, INC.

1200 Brickell Avenue, Suite 1950 #1183